These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005). Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782 [TBL] [Abstract][Full Text] [Related]
6. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci. Napolitano LM Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494 [TBL] [Abstract][Full Text] [Related]
7. Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis. Johnson JA; Feeney ER; Kubiak DW; Corey GR Open Forum Infect Dis; 2015 Dec; 2(4):ofv156. PubMed ID: 26677455 [TBL] [Abstract][Full Text] [Related]
8. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus. Scheinfeld N J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167 [TBL] [Abstract][Full Text] [Related]
9. Role of Combination Antimicrobial Therapy for Vancomycin-Resistant Enterococcus faecium Infections: Review of the Current Evidence. Yim J; Smith JR; Rybak MJ Pharmacotherapy; 2017 May; 37(5):579-592. PubMed ID: 28273381 [TBL] [Abstract][Full Text] [Related]
10. New antimicrobial agents as therapy for resistant gram-positive cocci. Lentino JR; Narita M; Yu VL Eur J Clin Microbiol Infect Dis; 2008 Jan; 27(1):3-15. PubMed ID: 17899228 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic options for vancomycin-resistant enterococcal bacteremia. Barber KE; King ST; Stover KR; Pogue JM Expert Rev Anti Infect Ther; 2015 Mar; 13(3):363-77. PubMed ID: 25661903 [TBL] [Abstract][Full Text] [Related]
12. Optimizing therapy for vancomycin-resistant enterococcal bacteremia in children. Tamma PD; Hsu AJ Curr Opin Infect Dis; 2014 Dec; 27(6):517-27. PubMed ID: 25313503 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci. Wu T; Meyer K; Harrington AT; Danziger LH; Wenzler E J Antimicrob Chemother; 2019 May; 74(5):1300-1305. PubMed ID: 30753495 [TBL] [Abstract][Full Text] [Related]
14. Molecular Epidemiology of Vancomycin-Resistant Enterococcus faecalis and Enterococcus faecium Isolated from Clinical Specimens in the Northwest of Iran. Jahansepas A; Ahangarzadeh Rezaee M; Hasani A; Sharifi Y; Rahnamaye Farzami M; Dolatyar A; Aghazadeh M Microb Drug Resist; 2018 Oct; 24(8):1165-1173. PubMed ID: 29708837 [TBL] [Abstract][Full Text] [Related]
15. Emergence and management of drug-resistant enterococcal infections. Arias CA; Murray BE Expert Rev Anti Infect Ther; 2008 Oct; 6(5):637-55. PubMed ID: 18847403 [TBL] [Abstract][Full Text] [Related]
16. Beyond Vancomycin: The Tail of the Lipoglycopeptides. Klinker KP; Borgert SJ Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277 [TBL] [Abstract][Full Text] [Related]